Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Molecular Profile Hints at Inflammatory Processes in Chronic Fatigue

Lisa Rapaport  |  August 2, 2017

(Reuters Health)—People with severe symptoms of chronic fatigue syndrome have a molecular signature in blood made up of 17 immune system signaling molecules that are elevated, which may provide insight into how inflammation contributes to the condition.

“Of the 17 cytokines that correlated with severity, 13 are proinflammatory, likely contributing to many of the symptoms experienced by patients and establishing a strong immune system component of the disease,” write Dr. Jose G. Montoya of Stanford University School of Medicine in California and colleagues in the Proceedings of the National Academy of Sciences, online July 31.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Millions of people worldwide, including more than 1 million in the U.S. alone, suffer from chronic fatigue syndrome, they note.

The condition, also called myalgic encephalomyelitis, may be diagnosed when people have at least six months of debilitating fatigue that can’t be explained by other causes and make it difficult for them to keep up with school, work or social activities. Symptoms can appear in different combinations and intensities and may include sleep problems, cognitive impairment, fever, sore throat, or sensitivity to noise, light or certain foods.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Many, but not all, chronic fatigue syndrome patients experience flu-like symptoms common in diseases caused by inflammation, they add.

For the current study, the researchers examined blood samples from 192 patients with chronic fatigue syndrome and a control group of 392 healthy people.

The scientists found that some cytokine levels were lower in patients with mild forms of chronic fatigue syndrome than in the group of healthy individuals, but higher in people with severe symptoms of chronic fatigue syndrome.

One cytokine in particular, tumor growth factor beta (TGF-beta), was higher in patients with chronic fatigue syndrome than in the healthy controls, while another protein, resistin, was lower.

However, the study team also found that the concentrations of 17 of the 51 cytokines they examined were associated with disease severity. Thirteen of those 17 cytokines are pro-inflammatory, the authors note.

Taken together, the findings build on previous research demonstrating that chronic fatigue syndrome is a real illness, and not something patients make up or experience only for psychological reasons, experts say.

“Many people with (chronic fatigue syndrome) report that their illness began with symptoms associated with a typical respiratory infection including fever, sore throat, swollen lymph nodes, muscle weakness and fatigue, but the clinical course was atypical and they never fully recovered,” says Dr. Ian Lipkin, a researcher at the Mailman School of Public Health at Columbia University in New York.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:chronic fatigue syndromeCytokinesinflammation

Related Articles

    Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

    October 17, 2017

    CHICAGO—Joseph Breen, PhD, program officer at the National Institutes of Health in Bethesda, Md., opened the chronic fatigue syndrome (CFS) session at the Federation of Clinical Immunology Societies (FOCIS) 2017 meeting by asking presenters to describe the current state of the science to the key immunology stakeholders gathered in the room. The hope was that…

    A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome

    September 26, 2017

    A session at the FOCIS 2017 meeting examined the current challenges and understanding of chronic fatigue syndrome, also called myalgic encephalomyelitis, in the hope of stimulating new approaches to deciphering the disease’s mechanistic and immunological underpinnings…

    Role of Dietitians in Rheumatology

    May 13, 2016

    What do dietitians do to help manage patients with rheumatic disease? Dietitians are well integrated, for example, in the practice of nephrology and diabetes, but few are active in the specialty of rheumatology. However, dietitians are recognized as part of the team of providers designated to care for patients with rheumatic disease by the ACR….

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences